The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is targeting IRAK4 in patients with lymphoma promising?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, Is targeting the interleukin-1 receptor-associated kinase 4 (IRAK4) in patients with lymphoma promising?

Is targeting IRAK4 in patients with lymphoma promising?

IRAK4 is essential for signaling downstream of toll‑like receptors, which is critical for the expansion and proliferation of malignant B cells. Nowakowski discusses findings from a phase I study, evaluating a novel IRAK4 oral inhibitor in patients with non-Hodgkin lymphoma.

Share: